Floatz logo

Alemtuzumab

Myelodysplastic/Myeloproliferative Neoplasm

Fred Hutchinson Cancer Centermonoclonal_antibodyPhase 2Dormant
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
95/ 100

Competitive context

42 Active assets in the Myelodysplastic/Myeloproliferative Neoplasm cohort.

Asset / SponsorPhaseRating
Etoposide
M.D. Anderson Cancer Center
Phase 3BBB
Melphalan
M.D. Anderson Cancer Center
Phase 2/3BBB
Cyclosporin A
Memorial Sloan Kettering Cancer Center
Phase 3BBB
Cytarabine
Fred Hutchinson Cancer Center
Phase 3BBB
Busulfanum
Jacqueline Garcia, MD
Phase 2/3BBB

View all 50 →

Same molecule, other indications

Alemtuzumab is also rated in:

relapsing-remitting multiple sclerosisActive
BBB
Indicative · Phase 4
73 / 100
View asset →
chronic myeloid leukemiaActive
BB
Indicative · Phase 2/3
71 / 100
View asset →
B-cell chronic lymphocytic leukemiaDormant
BB
Indicative · Phase 3
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →